Wuhan YZY Biopharma Co., Ltd. (HKG:2496)

Market Cap	1.00B +14.7%
Revenue (ttm)	74.40M -38.0%
Net Income	-94.29M
EPS	-0.49
Shares Out	193.85M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,400
Open	4.300
Previous Close	5.160
Day's Range	4.300 - 4.300
52-Week Range	3.900 - 8.400
Beta	0.49
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 27, 2026

About Wuhan YZY Biopharma

Wuhan YZY Biopharma Co., Ltd., a biotechnology company, develops bispecific antibody-based therapies for the treatment of cancer, cancer-associated complications, and age-related ophthalmologic diseases. It develops various product candidates for the treatment of malignant ascites, malignant pleural effusion, solid tumors, pancreatic cancer, hepatocellular carcinoma, and other advanced solid tumors; wAMD, DME, and other ocular neovascularization-related diseases; hemophilia; and inflammatory bowel diseases. The company was founded in 2010 and i...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 106
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2496

Financial Performance

In 2025, Wuhan YZY Biopharma's revenue was 66.86 million, a decrease of -37.99% compared to the previous year's 107.81 million. Losses were -84.73 million, -13.18% less than in 2024.

Financial numbers in CNY